Recent Updates
Recently added Catalysts
SPRO Positive Sentiment

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Monday, July 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spero Therapeutics, a clinical-stage biopharmaceutical company, has scheduled a conference call for August 5, 2024, to report its financial results for the second quarter of 2024. The call will also provide an update on the company's business and pipeline. Interested parties can access the call via a dedicated phone line or through a live audio webcast. The archived audio will be available on Spero's website for 30 days after the event.
Price reaction · baseline $1.435 (2024-07-26 close) · clean, no other SPRO news in the window
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Spero Therapeutics is actively engaging with investors by hosting a conference call.
  • The company is focused on developing novel treatments for rare diseases and MDR infections.
  • The upcoming financial results announcement indicates ongoing business activity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
7.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromide
Phase 1 · Renal Impairment

Full Press Release Details

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.
To access the call, please dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and refer to conference ID 13747505, or click on this link and request a return call. The audio webcast can be accessed live on this link and also on the “Investor Relations” page of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information -  www.sperotherapeutics.com
Investor Relations Contact:

Frequently Asked Questions

When will Spero Therapeutics hold its conference call?

Spero Therapeutics will host a conference call on August 5th, 2024, at 4:30 p.m. ET.

How can I access the conference call?

To join, call 1-877-269-7751 for domestic or 1-201-389-0908 internationally, using ID 13747505.

Where can I find the webcast of the call?

The audio webcast will be available on Spero's website and the Investor Relations page.

What will be discussed during the conference call?

Management will report second quarter 2024 financial results and provide business updates.

How long will the archived webcast be available?

The archived webcast will be accessible for 30 days after the conference call.

ShareAdd on Google
Tags: SPRO Viatris Investor Conferences Healthcare Spero Therapeutics financial results Q2 2024 business update
Last updated: Jul 29, 2024

Biotech snapshot

Cash runway
$51M liquidity · $2M/mo burn
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromidePhase 1
Renal Impairment →

Catalyst track record

+8%
best trade around SPRO's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for SPRO.

See every catalyst's timing & PoA →